Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US news (Ticker: APUS), a resource for investors and traders seeking the latest updates and insights on APIMEDS PHARMACEUTICALS US stock.
Apimeds Pharmaceuticals US, Inc. develops non-opioid, biologic-based therapies for pain management as a clinical-stage biopharmaceutical company. Company news centers on Apitox, also referenced as LT-100, a pure honeybee venom biologic candidate for signs and symptoms of osteoarthritis, with historical approval in South Korea under the Apitoxin name.
Recurring updates also cover U.S. regulatory interactions, clinical-development planning, material agreements, shareholder voting and governance matters, capital-structure disclosures, and operating results. Apimeds has also announced ai² Futures Lab collaborations tied to evaluation of early-stage pharmaceutical assets and biopharma business development projects.
MindWave Innovations (NYSE American: APUS), a subsidiary of Apimeds Pharmaceuticals US, announced that its NILA token is now available to eligible U.S. users on Webot, a licensed U.S. cryptocurrency exchange registered as an MSB with FinCEN and holding Money Transmitter Licenses in 48 states (NMLS #2284360).
The listing provides U.S. access to NILA ahead of its planned migration to MindChain, an insured Layer 2 network on Ethereum expected to launch in October 2026, subject to completion of legal, regulatory, technical, and compliance requirements. A test network is planned for August–September 2026, with a migration portal and token tools expected at MindChain go‑live.
Apimeds Pharmaceuticals US (NYSE American: APUS), via wholly owned subsidiary MindWave Innovations, announced MindChain, described as the world's first fully insured, EVM-compatible Layer 2 blockchain, scheduled for mainnet launch in October 2026 with Ethereum as the settlement and data availability layer.
The company also disclosed that its NILA token will become available to U.S. users on Webot, a licensed U.S. crypto exchange with Money Transmitter Licenses in 48 states, starting August 3, 2026, ahead of NILA becoming MindChain’s native gas and staking token.
Apimeds Pharmaceuticals US (NYSE American: APUS) reached a settlement with Inscobee parties to resolve disputes from its Dec 1, 2025 merger. The agreement clears the way to complete merger transactions, close a $100 million PIPE financing, resume NYSE American trading on May 5, 2026, and advance the Apitox program via newly formed Lōkahi Therapeutics.
The deal assigns Apitox assets to Lōkahi, delivers $4.0 million to APUS, transfers a $2.2 million Prevail CRO credit facility, allocates 10% of financing net proceeds to a Newco, and directs a 51% Lōkahi distribution as specified by Erik Emerson.
Apimeds Pharmaceuticals US (NYSE:APUS) stockholders led by Inscobee and Apimeds Korea delivered a written consent on March 20, 2026 removing four directors and appointing three new directors, reducing the board to three and naming Youngjik Cho as CEO effective immediately.
The majority holders claim the Written Consent is valid; MindWave issued a separate release disputing that validity and threatening litigation. The majority cites concerns about MindWave's alleged 1000 bitcoin ownership in the prior Merger.
Summary not available.
Apimeds Pharmaceuticals (NASDAQ:APUS) and Lōkahi Therapeutics said the FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine confirmed a Type C meeting for LT-100 (Apitox) on May 4, 2026 via teleconference. The meeting follows a Type C request and aims to align on key development considerations for LT-100 in the U.S.
LT-100 is pure honeybee venom previously approved for marketing in South Korea; the developers are integrating historical data, performing manufacturing process enhancements, and seeking FDA alignment on the U.S. regulatory path.
Apimeds Pharmaceuticals (NYSE American: APUS) closed a $100 million PIPE financing and completed integration steps with MindWave Innovations, strengthening liquidity to advance late-stage non-opioid therapeutic programs toward clinical and regulatory milestones. As part of the integration, ~1,000 Bitcoin held by MindWave were transferred into a segregated, risk-managed treasury governed by a defined investment policy to pursue AI-driven yield generation while preserving capital. The company said further updates on clinical progress, treasury deployment, and integration will follow in coming weeks.
Apimeds (NYSE American: APUS) announced a merger with MindWave to combine Apimeds’ late-stage, non-opioid biologic portfolio (lead candidate Apitox) with MindWave’s AI-driven institutional Digital Asset Treasury platform. The transaction is supported by a concurrent PIPE of up to $100 million to fund Apimeds’ clinical programs and expand MindWave infrastructure. Apimeds completed its IPO in May 2025 and plans to transfer Apimeds assets into a wholly owned subsidiary post-closing. The combined company targets diversified revenue from biotechnology and digital-asset treasury services, including secure corporate Bitcoin wallets, AI-enhanced Bitcoin yield, and a validator ecosystem powered by $NILA.
Regulatory filings with the SEC and an Information Statement under Section 14(c) will follow; the release highlights integration, financing, listing, and bitcoin-volatility risks.
Apimeds (NYSE American: APUS) is expanding its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, starting Spring 2026. The program pairs University of Idaho MBA and student teams with Apimeds mentors to evaluate early-stage pharmaceutical assets, perform market and IP analysis, and develop commercial strategies.
The University of Idaho joins University of Alabama, University of San Diego and University of Oregon in the ai² Futures Lab network, which combines human insight with AI analytics to support biotech innovation and experiential learning.
Apimeds Pharmaceuticals (NYSE: APUS) announced a new collaboration between its ai² Futures Lab program and the University of Oregon’s Lundquist College of Business, beginning Winter 2026. The partnership will place student teams with Apimeds mentors to evaluate early-stage or shelved pharmaceutical assets, conduct market and IP analysis, and identify business strategies to advance patient care.
The University of Oregon is the third academic partner after the University of Alabama and University of San Diego. Apimeds says the program pairs human insight with AI-driven analytics to surface therapeutic opportunities and train future industry leaders.